Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.addr.2015.07.003
DC FieldValue
dc.titleHydrogels for therapeutic cardiovascular angiogenesis
dc.contributor.authorRufaihah, Abdul Jalil
dc.contributor.authorSeliktar, Dror
dc.date.accessioned2022-04-21T08:12:12Z
dc.date.available2022-04-21T08:12:12Z
dc.date.issued2016-01-15
dc.identifier.citationRufaihah, Abdul Jalil, Seliktar, Dror (2016-01-15). Hydrogels for therapeutic cardiovascular angiogenesis. ADVANCED DRUG DELIVERY REVIEWS 96 : 31-39. ScholarBank@NUS Repository. https://doi.org/10.1016/j.addr.2015.07.003
dc.identifier.issn0169-409X
dc.identifier.issn1872-8294
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/219448
dc.description.abstractAcute myocardial infarction (MI) caused by ischemia is the most common cause of cardiac dysfunction. While growth factor or cell therapy is promising, the retention of bioactive agents in the highly vascularized myocardium is limited and prevents sustained activation needed for adequate cellular responses. Various types of biomaterials with different physical and chemical properties have been developed to improve the localized delivery of growth factor and/or cells for therapeutic angiogenesis in ischemic tissues. Hydrogels are particularly advantageous as carrier systems because they are structurally similar to the tissue extracellular matrix (ECM), they can be processed under relatively mild conditions and can be delivered in a minimally invasive manner. Moreover, hydrogels can be designed to degrade in a timely fashion that coincides with the angiogenic process. For these reasons, hydrogels have shown great potential as pro-angiogenic matrices. This paper reviews a few of the hydrogel systems currently being applied together with growth factor delivery and/or cell therapy to promote therapeutic angiogenesis in ischemic tissues, with emphasis on myocardial applications.
dc.language.isoen
dc.publisherELSEVIER SCIENCE BV
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectPharmacology & Pharmacy
dc.subjectBiomaterial
dc.subjectMyocardial infarction
dc.subjectGrowth factor delivery
dc.subjectCell therapy
dc.subjectIschemia
dc.subjectMinimally invasive
dc.subjectFIBROBLAST-GROWTH-FACTOR
dc.subjectMESENCHYMAL STEM-CELLS
dc.subjectENDOTHELIAL PROGENITOR CELLS
dc.subjectPHOTOCROSSLINKABLE CHITOSAN HYDROGEL
dc.subjectMYOCARDIAL-INFARCTION
dc.subjectIN-VITRO
dc.subjectPOLY(ETHYLENE GLYCOL)
dc.subjectFIBRIN MATRICES
dc.subjectFACTOR DELIVERY
dc.subjectSUSTAINED DELIVERY
dc.typeReview
dc.date.updated2022-04-21T01:44:53Z
dc.contributor.departmentDEAN'S OFFICE (MEDICINE)
dc.contributor.departmentNUS NANOSCIENCE & NANOTECH INITIATIVE
dc.description.doi10.1016/j.addr.2015.07.003
dc.description.sourcetitleADVANCED DRUG DELIVERY REVIEWS
dc.description.volume96
dc.description.page31-39
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
advanced drug delivery reviews.pdf613.47 kBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

63
checked on Dec 2, 2022

Page view(s)

61
checked on Dec 1, 2022

Download(s)

1
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.